Oxford Biomedica (LON:OXB) Sets New 1-Year Low – Here’s Why

Shares of Oxford Biomedica plc (LON:OXB) reached a new 52-week low on Tuesday . The stock traded as low as GBX 431 and last traded at GBX 436.55, with a volume of 1907452 shares trading hands. The stock had previously closed at GBX 524.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Stock Performance

The firm has a fifty day moving average price of GBX 563.12 and a 200 day moving average price of GBX 603.87. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. The stock has a market cap of £524.79 million, a PE ratio of -16.11 and a beta of 1.10.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.